Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $36,200 | 43 | 53.3% |
| Honoraria | $13,600 | 9 | 20.0% |
| Food and Beverage | $11,743 | 532 | 17.3% |
| Consulting Fee | $4,500 | 2 | 6.6% |
| Travel and Lodging | $1,774 | 9 | 2.6% |
| Education | $96.75 | 2 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| US WorldMeds, LLC | $15,170 | 43 | $0 (2020) |
| Amneal Pharmaceuticals LLC | $12,875 | 44 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $12,373 | 44 | $0 (2024) |
| Acorda Therapeutics, Inc | $11,714 | 33 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $7,234 | 27 | $0 (2021) |
| ABBVIE INC. | $1,569 | 76 | $0 (2024) |
| UCB, Inc. | $695.92 | 46 | $0 (2024) |
| Allergan, Inc. | $591.75 | 44 | $0 (2022) |
| Neurocrine Biosciences, Inc. | $493.61 | 17 | $0 (2024) |
| Abbott Laboratories | $473.04 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,588 | 53 | ABBVIE INC. ($618.70) |
| 2023 | $1,522 | 63 | AbbVie Inc. ($396.70) |
| 2022 | $5,257 | 71 | Amneal Pharmaceuticals LLC ($3,818) |
| 2021 | $11,145 | 48 | Amneal Pharmaceuticals LLC ($4,767) |
| 2020 | $17,283 | 78 | Acorda Therapeutics, Inc ($9,071) |
| 2019 | $1,588 | 83 | Acorda Therapeutics, Inc ($412.25) |
| 2018 | $14,789 | 113 | US WorldMeds, LLC ($7,199) |
| 2017 | $14,743 | 88 | US WorldMeds, LLC ($7,893) |
All Payment Transactions
597 individual payment records from CMS Open Payments — Page 1 of 24
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $24.35 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/09/2024 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | Food and Beverage | In-kind items and services | $23.57 | General |
| Category: Musculoskeletal | ||||||
| 12/04/2024 | UCB, Inc. | Zilbrysq (Drug) | Food and Beverage | In-kind items and services | $22.70 | General |
| Category: Neurology | ||||||
| 12/02/2024 | ABBVIE INC. | BOTOX (Biological), QULIPTA | Food and Beverage | In-kind items and services | $28.57 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 10/31/2024 | ABBVIE INC. | VYALEV (Drug), DUOPA | Food and Beverage | In-kind items and services | $20.46 | General |
| Category: NEUROSCIENCE | ||||||
| 10/30/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $24.61 | General |
| Category: PAIN | ||||||
| 10/29/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $26.82 | General |
| Category: NEUROSCIENCE | ||||||
| 10/23/2024 | Kyowa Kirin, Inc. | Nourianz (Drug) | Food and Beverage | In-kind items and services | $18.74 | General |
| Category: Adenosine A2A Receptors | ||||||
| 10/21/2024 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $20.32 | General |
| Category: EPILEPSY | ||||||
| 10/15/2024 | MITSUBISHI TANABE PHARMA AMERICA, INC. | RADICAVA (Drug), RADICAVA ORS | Food and Beverage | In-kind items and services | $34.99 | General |
| Category: AMYOTROPHIC LATERAL SCLEROSIS | ||||||
| 10/02/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $34.19 | General |
| Category: Neuropsychiatry | ||||||
| 10/01/2024 | Amneal Pharmaceuticals LLC | ONGENTYS (Drug) | Food and Beverage | In-kind items and services | $15.81 | General |
| Category: NEUROLOGY | ||||||
| 09/24/2024 | InSightec,Inc | Exablate (Device) | Food and Beverage | Cash or cash equivalent | $21.50 | General |
| Category: Neurology | ||||||
| 09/23/2024 | PFIZER INC. | OCTAGAM IMMUNE GLOBULIN (HUMAN) (Drug), PANZYGA | Food and Beverage | In-kind items and services | $21.80 | General |
| Category: IMMUNOLOGY | ||||||
| 09/18/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $12.25 | General |
| Category: NEUROSCIENCE | ||||||
| 09/04/2024 | CATALYST PHARMACEUTICALS, INC. | FIRDAPSE (Drug) | Food and Beverage | Cash or cash equivalent | $37.93 | General |
| Category: NEUROLOGY | ||||||
| 09/03/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $33.16 | General |
| Category: Rare Disease | ||||||
| 08/28/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $21.82 | General |
| Category: Central Nervous System | ||||||
| 08/27/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $33.07 | General |
| Category: Rare Disease | ||||||
| 08/27/2024 | ABBVIE INC. | DUOPA (Drug) | Food and Beverage | In-kind items and services | $18.86 | General |
| Category: NEUROSCIENCE | ||||||
| 08/21/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $19.07 | General |
| Category: PSYCHIATRY | ||||||
| 08/20/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $22.27 | General |
| Category: NEUROSCIENCE | ||||||
| 08/19/2024 | REVANCE THERAPEUTICS, INC. | DAXXIFY (Drug) | Food and Beverage | In-kind items and services | $24.16 | General |
| Category: AESTHETICS AND THERAPEUTICS | ||||||
| 08/09/2024 | ABBVIE INC. | DUOPA (Drug) | Food and Beverage | In-kind items and services | $15.38 | General |
| Category: NEUROSCIENCE | ||||||
| 08/05/2024 | Takeda Pharmaceuticals U.S.A., Inc. | HYQVIA (Biological) | Food and Beverage | In-kind items and services | $42.47 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 1,949 | 26,720 | $846,256 | $360,508 |
| 2022 | 22 | 1,891 | 22,009 | $764,168 | $327,538 |
| 2021 | 22 | 2,122 | 24,795 | $887,683 | $391,121 |
| 2020 | 24 | 2,094 | 21,743 | $740,291 | $322,932 |
All Medicare Procedures & Services
89 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 791 | 1,287 | $281,853 | $115,235 | 40.9% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 71 | 22,792 | $227,920 | $112,779 | 49.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 333 | 384 | $57,984 | $23,104 | 39.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 144 | 173 | $50,862 | $22,925 | 45.1% |
| J0587 | Injection, rimabotulinumtoxinb, 100 units | Office | 2023 | 18 | 1,300 | $31,200 | $12,995 | 41.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 78 | 78 | $32,838 | $12,241 | 37.3% |
| 64616 | Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | Office | 2023 | 24 | 68 | $17,612 | $10,322 | 58.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 78 | 79 | $32,785 | $10,094 | 30.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 74 | 74 | $20,942 | $7,166 | 34.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 62 | 62 | $20,646 | $7,131 | 34.5% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2023 | 19 | 39 | $11,934 | $4,828 | 40.5% |
| 64611 | Injection of chemical for paralysis of salivary glands on both sides of mouth | Office | 2023 | 19 | 46 | $12,036 | $4,670 | 38.8% |
| 64642 | Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | Office | 2023 | 20 | 35 | $10,080 | $3,974 | 39.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 47 | 49 | $7,252 | $3,067 | 42.3% |
| 95983 | Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | Office | 2023 | 40 | 74 | $7,918 | $2,833 | 35.8% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 30 | 46 | $4,968 | $1,697 | 34.1% |
| 95984 | Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | Office | 2023 | 20 | 47 | $4,371 | $1,587 | 36.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 16 | $3,408 | $1,507 | 44.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 16 | 16 | $3,472 | $1,179 | 33.9% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2023 | 20 | 20 | $2,360 | $737.94 | 31.3% |
| 95970 | Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator | Office | 2023 | 32 | 35 | $3,815 | $437.32 | 11.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 760 | 1,276 | $279,444 | $117,787 | 42.2% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 60 | 18,701 | $187,005 | $89,931 | 48.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 406 | 472 | $71,272 | $28,994 | 40.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 124 | 146 | $42,924 | $19,225 | 44.8% |
About Dr. Dean Sutherland, MD
Dr. Dean Sutherland, MD is a Neurology healthcare provider based in Sarasota, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1346251089.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Dean Sutherland, MD has received a total of $67,914 in payments from pharmaceutical and medical device companies, with $1,588 received in 2024. These payments were reported across 597 transactions from 60 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($36,200).
As a Medicare-enrolled provider, Sutherland has provided services to 8,056 Medicare beneficiaries, totaling 95,267 services with total Medicare billing of $1.4M. Data is available for 4 years (2020–2023), covering 89 distinct procedure/service records.
Practice Information
- Specialty Neurology
- Location Sarasota, FL
- Active Since 08/10/2006
- Last Updated 03/16/2020
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1346251089
Products in Payments
- Xadago (Drug) $14,962
- RYTARY (Drug) $12,886
- INBRIJA (Drug) $11,668
- AUSTEDO (Drug) $8,436
- KYNMOBI (Drug) $7,055
- SD809-HD (Drug) $3,583
- BOTOX (Biological) $775.13
- Neupro (Drug) $580.77
- INFINITY (Device) $473.04
- INGREZZA (Drug) $405.79
- DUOPA (Drug) $371.11
- GOCOVRI (Drug) $357.91
- UBRELVY (Drug) $323.03
- NUPLAZID (Drug) $315.91
- SOLIRIS (Drug) $196.06
- Duopa (Drug) $182.12
- APTIOM (Drug) $178.62
- QULIPTA (Drug) $177.34
- AIMOVIG (Biological) $176.53
- Exablate (Device) $171.11
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Sarasota
Donald Negroski, Md, MD
Neurology — Payments: $1.8M
Dr. V Kassicieh, D.o, D.O
Neurology — Payments: $403,795
Mauricio Concha, Md, MD
Neurology — Payments: $274,642
Gregory Hanes, Md, MD
Neurology — Payments: $261,651
Ricardo Gonzalez, Md, MD
Neurology — Payments: $74,673
Dr. Ronald Aung-Din, M.d, M.D
Neurology — Payments: $45,214